通过衔接型双特异性T细胞衔接器武装的抗体 panel 介导双重淋巴激活以强化抗骨髓瘤治疗
研究开发了衔接型双特异性T细胞衔接器(B-BiTE),可同时结合人IgG-Fc段与CD3分子;临床可用单克隆抗体与B-BiTE预结合后给药,形成的mAb/B-BiTE复合物在保留并支持自然杀伤细胞反应性的同时诱导抗肿瘤T细胞应答,通过双重淋巴激活增强抗骨髓瘤效果;序贯使用两种不同mAb/B-BiTE复合物似乎可规避骨髓瘤细胞抗原逃逸,并较单药mAb/B-BiTE或两种mAb序贯(无B-BiTE)进一步放大免疫应答。
要点
- B-BiTE可结合人IgG-Fc段和CD3,与临床可用mAb预结合形成复合物。
- mAb/B-BiTE复合物诱导抗肿瘤T细胞应答并保留NK细胞反应性,实现双重淋巴激活。
- 序贯两种mAb/B-BiTE复合物似乎可规避骨髓瘤细胞抗原逃逸并增强免疫应答。
核心结论
- 该模式可便捷、快速生成广谱双特异性抗体,在临床可用mAb存在下诱导深度且持久的抗肿瘤应答,支持进一步推进骨髓瘤及其他难治性血液恶性肿瘤的强化免疫治疗。
研究设计与样本
- 研究新开发了基于BiTE的衔接型双特异性T细胞衔接器(B-BiTE),可结合人IgG-Fc段与CD3分子,并在体外和体内评估其与临床可用mAb预结合后的抗骨髓瘤效果。
主要发现
- mAb/B-BiTE复合物成功诱导抗肿瘤T细胞应答,同时保留并支持自然杀伤细胞反应性,通过双重淋巴激活增强抗骨髓瘤效果。
- mAb/B-BiTE复合物或B-BiTE本身介导的非靶向免疫细胞反应性在体外和体内似乎未观察到。
- 序贯使用两种不同mAb/B-BiTE复合物似乎可规避骨髓瘤细胞抗原逃逸,并较mAb/B-BiTE单药或两种mAb序贯(无B-BiTE)进一步放大对骨髓瘤的免疫应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy using bispecific antibodies including bispecific T-cell engager (BiTE) has the potential to enhance the efficacy of treatment for relapsed/refractory multiple myeloma. However, myeloma may still recur after treatment because of downregulation of a target antigen and/or myeloma cell heterogeneity. To strengthen immunotherapy for myeloma while overcoming its characteristics, we have newly developed a BiTE-based modality, referred to as bridging-BiTE (B-BiTE). B-BiTE was able to bind to both a human immunoglobulin G-Fc domain and the CD3 molecule. Clinically available monoclonal antibodies (mAbs) were bound with B-BiTE before administration, and the mAb/B-BiTE complex induced antitumor T-cell responses successfully while preserving and supporting natural killer cell reactivity, resulting in enhanced antimyeloma effects via dual-lymphoid activation. In contrast, any unwanted off-target immune-cell reactivity mediated by mAb/B-BiTE complexes or B-BiTE itself appeared not to be observed in vitro and in vivo. Importantly, sequential immunotherapy using 2 different mAb/B-BiTE complexes appeared to circumvent myeloma cell antigen escape, and further augmented immune responses to myeloma relative to those induced by mAb/B-BiTE monotherapy or sequential therapy with 2 mAbs in the absence of B-BiTE. Therefore, this modality facilitates easy and prompt generation of a broad panel of bispecific antibodies that can induce deep and durable antitumor responses in the presence of clinically available mAbs, supporting further advancement of reinforced immunotherapy for multiple myeloma and other refractory hematologic malignancies.
引用
- Konishi T, Ochi T, Maruta M, et al. Reinforced antimyeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with bridging-BiTE. Blood. 2023. PMID: 37738633. doi:10.1182/blood.2022019082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。